M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera PharmaphorumJazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaphorum Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls shortNext: uniQure sets course to US filing for Huntington gene therapy Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
